Skip to main content

A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.

Mulder CV, Jongbloed EM, Liefaard MC, Makrodimitris S, Hazelaar DM, Beaufort CM, de Weerd V, Mulder L, van Deurzen CHM, Sonke GS, Jager A, Wilting SM, Martens JWM, Jansen MPHM, Lips EH

Publication: Breast Cancer Res (2025) • Vol 27 • Page 120PMID: 40598388View on PubMed

Purpose

This paper compared the detection of circulating tumor DNA (ctDNA) in plasma using four different next-generation sequencing (NGS) assays and investigated whether patient age or tumor characteristics influenced detection.

Conclusion

There were no significant differences in patient age or tumor characteristics (distributions by subtype, clinical T stage, clinical N stage, grade or pathological response) between the 40 specimens chosen for analysis (sufficient DNA for ≥3 assays) and the 16 specimens excluded. Among the 24 specimens assayed with the Oncomine NGS assay, 3 specimens had mutations: a TP53 mutation with a variant allele frequency (VAF) of 28.5%, a TP53 mutation with a VAF of 1.1% and a PIK3CA mutation with a VAF of 7.5%. The specimen with a VAF of 28.5% for TP53 was also found to have an elevated aneuploidy score using the mFAST-SeqS assay, a tumor fraction >0 in shallow whole genome sequencing (sWGS) and a positive (z-score above the 95% confidence interval for differentially methylated genes) genome-wide NGS methylation profiling (MeD-Seq). In a specimen with a VAF of 7.5% for PIK3CA in the Oncomine assay, a mutation with a tumor fraction >0 was found by sWGS but only after analysis was restricted to fragments of 90-150 bp and the specimen was negative using the MeD-Seq Assay and the genome-wide NGS CNV assay (mFAST-Seq). The remaining specimen that was positive in the Oncomine assay for TP53 mutation (VAF 1.1%) was negative in the other three assays. An elevated aneuploidy score (mFAST-SeqS) was found in a total of five specimens, including the aforementioned specimen positive in all four assays, three specimens that were negative (one was not assessed) in Oncomine but positive using MeD-Seq, and one that had a tumor fraction > 0 using sWGS but was negative in the other assays.  There weren’t any specimens that were positive using sWGS but negative in Oncomine and mFAST-Seq assays. In addition to the four aforementioned specimens, 19 specimens were positive in the MeD-Seq assay and negative using all other assays. Positivity (a positive in ≥1 assay) in one or more assays occurred in 65% of specimens but was not affected by patient age, tumor characteristics (subtype, clinical T stage, clinical N stage, grade or pathological response) or cfDNA concentration.

Studies (1)

Purpose

This study compared the detection of circulating tumor DNA (ctDNA) using four different next-generation sequencing (NGS) assays and investigated whether patient age or tumor characteristics influenced detection.  Blood was collected from 56 patients with tri­ple negative (TN) or luminal B type breast cancer into EDTA, CellSave or Streck tubes (number of each not specified). Plasma was obtained by centrifugation at 1,711 g for 10 min at room tempera­ture, followed by 12,000 g for 10 min at 4⁰C within 4 h (EDTA) or 72 h (CellSave/Streck) of venipuncture. Plasma was stored at -80°C until cfDNA isolation with the QiaAmp Kit. cfDNA was quantified using the Quant-IT dsDNA high-sensitivity Assay and stored at -30°C until analysis. Single-nucleotide variants were detected in 24 specimens by Next-Generation sequencing (NGS) using the Oncomine Breast cfDNA panel. Copy number variants (CNVs) were detected by NGS in 40 specimens using the mFAST-seqS method and were considered aneuploid if the aneuploid score was ≥5. Methylation was assessed in 40 specimens by NGS. Methylated reads within 1,000 bp of the transcription start site were counted, differentially methylated regions were identified, Z-scores were calculated and positivity was defined as a z-score > than the 95% confidence interval. CNVs were detected in 40 specimens by shallow genome-wide NGS using the ThruPLEX DNA-Seq Kit and a Illumina NEXTsq2000 instrument. Tumor fraction and CNV were calculated from shallow sequencing data using the IchorCNA package.

Summary of Findings

There were no significant differences in patient age or tumor characteristics (distributions by subtype, clinical T stage, clinical N stage, grade or pathological response) between the 40 specimens chosen for analysis (sufficient DNA for ≥3 assays) and the 16 specimens excluded. Among the 24 specimens assayed with the Oncomine NGS assay, 3 specimens had mutations: a TP53 mutation with a VAF of 28.5%, a TP53 mutation with a VAF of 1.1% and a PIK3CA mutation with a VAF of 7.5%. The specimen with a VAF of 28.5% for TP53 was also found to have an elevated aneuploidy score using the mFAST-SeqS assay, a tumor fraction >0 in shallow whole genome sequencing (sWGS) and a positive (z-score above the 95% confidence interval for differentially methylated genes) genome-wide NGS methylation profiling (MeD-Seq). In a specimen with a VAF of 7.5% for PIK3CA in the Oncomine assay, a mutation with a tumor fraction >0 was found by sWGS but only after analysis was restricted to fragments of 90-150 bp and the specimen was negative using the MeD-Seq Assay and the genome-wide NGS CNV assay (mFAST-Seq). The remaining specimen that was positive in the Oncomine assay for TP53 mutation (VAF 1.1%), was negative in the other three assays. An elevated aneuploidy score (mFAST-SeqS) was found in a total of five specimens including the aforementioned specimen positive in all four assays, three specimens that were negative (one was not assessed) in Oncomine but positive using MeD-Seq, and one that had a tumor fraction > 0 using sWGS but was negative in the other assays.  There weren’t any specimens that were positive using sWGS but negative in Oncomine and mFAST-Seq assays. In addition to the four aforementioned specimens, 19 specimens were positive in the MeD-Seq assay and negative using all other assays. Positivity (a positive in ≥1 assay) in one or more assays occurred in 65% of specimens but was not affected by patient age, tumor characteristics (subtype, clinical T stage, clinical N stage, grade or pathological response) or cfDNA concentration.

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    Streck/BCTFrozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNANext generation sequencing
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Luminal B type breast cancer
    Triple negative breast cancer
    PreaquisitionPatient age
    Unspecified Range
    PreaquisitionPrognostic factor
    Complete response
    High grade
    Intermediate grade
    Low grade
    N Stage negative
    N Stage positive
    Partial response
    Stage T1/T2
    Stage T3/T4
    Next generation sequencing SpecificTechnology platform
    MeD-Seq
    Oncomine
    mFAST-SeqS
    sWGS